Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Items 201–300 of 1,000
Biomarker in Colorectal Cancer
Schirripa, M., & Lenz, H. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000190 · Cited by 49
Self-citationYoshida, Y., Yamada, T., Kamiyama, H., Kosugi, C., Ishibashi, K., Yoshida, H., Ishida, H., Yamaguchi, S., Kuramochi, H., Fukazawa, A., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01794-8 · Cited by 46
Ben-Aharon, O., Magnezi, R., Leshno, M., & Goldstein, D. A. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0175 · Cited by 50
Fiore, F. D., Bouché, O., Lepage, C., Sefrioui, D., Gangloff, A., Schwarz, L., Tuech, J., Aparicio, T., Lecomte, T., Boulagnon‐Rombi, C., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.03.031 · Cited by 49
Chen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 50
André, T., Falcone, A., Shparyk, Y. V., Moiseenko, F. V., Polo, E., Csőszi, T., Bragagnoli, A. S. C., Liposits, G. I., Chmielowska, E., Aubel, P., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00334-x · Cited by 48
Self-citationEnzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy
Ricciuti, B., Foglietta, J., Bianconi, V., Sahebkar, A., & Pirro, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.005 · Cited by 50
Floudas, C. S., Brar, G. S., Mabry‐Hrones, D., Duffy, A. G., Wood, B. J., Levy, E. B., Krishnasamy, V. P., Fioravanti, S., Bonilla, C. M., Walker, M., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.06.004 · Cited by 51
Bachet, J., Wyrwicz, L. S., Price, T. J., Cremolini, C., Phelip, J., Portales, F., Özet, A., Çiçin, İ., Atlan, D., Becquart, M., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000698 · Cited by 55
Self-citationGabizón, A., Shmeeda, H., Tahover, E., Kornev, G., Patil, Y. P., Amitay, Y., Ohana, P., Sapir, E., & Zalipsky, S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.027 · Cited by 45
Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?
Raphael, M. J., & Karanicolas, P. J. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02505 · Cited by 47
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Bendell, J. C., Rosen, L. S., Mayer, R. J., Goldman, J. W., Infante, J. R., Benedetti, F. M., Lin, D., Mizuguchi, H., Zergebel, C., & Patel, M. R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2850-4 · Cited by 46
Self-citationMetronomic chemotherapy in metastatic colorectal cancer
Woo, I. S., & Jung, Y. H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.034 · Cited by 46
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
Stein, A., Moehler, M. H., Trojan, J., Goekkurt, E., & Vogel, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.001 · Cited by 49
EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy
Zhou, X., Wang, M., Katsyv, I., Irie, H., & Zhang, B. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty325 · Cited by 43
Re‐inventing the randomized controlled trial in medical oncology: The registry‐based trial
Foroughi, S., Wong, H., Gately, L., Lee, M., Simons, K., Tie, J., Burgess, A. W., & Gibbs, P. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12992 · Cited by 43
Andersen, S. E., Andersen, I. B., Jensen, B. V., Pfeiffer, P., Ota, T., & Larsen, J. S. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1605192 · Cited by 44
Ciracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 54
Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., Peng, K., Wu, D., Nurunnabi, M., Nelson, J. A., et al. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10166 · Cited by 42
Plana, D., Fell, G. G., Alexander, B. M., Palmer, A. C., & Sorger, P. K. (2022) · Nature Communications · doi:10.1038/s41467-022-28410-9 · Cited by 56
Gou, M., Qian, N., Zhang, Y., Yan, H., Si, H., Wang, Z., & Dai, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.851756 · Cited by 46
Hedayat, S., Cascione, L., Cunningham, D., Schirripa, M., Lampis, A., Hahne, J. C., Tunariu, N., Hong, S. P., Marchetti, S., Khan, K. H., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2748 · Cited by 46
Fujii, H., Matsuhashi, N., Kitahora, M., Takahashi, T., Hirose, C., Iihara, H., Yamada, Y., Watanabe, D., Ishihara, T., Suzuki, A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0541 · Cited by 45
Liver transplantation in metastatic colorectal cancer: are we ready for it?
Ros, J., Salvà, F., Dopazo, C., López-Valbuena, D., Gonzalez, N. S., Baraibar, I., Charco, R., Tabernero, J. M., & Élez, E. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02213-1 · Cited by 44
Self-citationKwakman, J. J. M., Vink, G. R., Vestjens, J. H. M. J., Beerepoot, L. V., de Groot, J. W., Jansen, R. L. H., Opdam, F. L., Boot, H., Creemers, G. J. M., van Rooijen, J. M., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1220-0 · Cited by 40
Cho, S. K., Hay, J. W., & Barzi, A. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.08.003 · Cited by 44
Emmons, E. C., Bishay, S., Du, L., Krebs, H. J., Gandhi, R. T., Collins, Z. S., O’Hara, R. G., Akhter, N. M., Wang, E. A., Grilli, C. J., et al. (2022) · Radiology · doi:10.1148/radiol.220387 · Cited by 41
Rocha, L. S. D. S., & Riechelmann, R. P. (2018) · Clinics · doi:10.6061/clinics/2018/e542s · Cited by 39
Casak, S. J., Horiba, M. N., Yuan, M., Cheng, J., Lemery, S. J., Shen, Y. L., Fu, W., Moore, J. N., Li, Y., Bi, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1041 · Cited by 43
Hecht, J. R., Park, Y. S., Tabernero, J. M., Lee, M. A., Lee, S. H., Manrique, A. C. V., den Eynde, M. V., Fontana, E., Fakih, M., Asghari, G., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02025-2 · Cited by 52
Self-citationEmerging Systemic Therapies for Colorectal Cancer
Krauss, J., & Veenstra, C. (2018) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0037-1602238 · Cited by 40
Daitoku, N., Miyamoto, Y., Tokunaga, R., Sakamoto, Y., Hiyoshi, Y., Iwatsuki, M., Baba, Y., Iwagami, S., Yoshida, N., & Baba, H. (2018) · Anticancer Research · doi:10.21873/anticanres.12802 · Cited by 42
Fanotto, V., Ongaro, E., Rihawi, K., Avallone, A., Silvestris, N., Fornaro, L., Vasile, E., Antonuzzo, L., Leone, F., Rosati, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11264 · Cited by 43
Raoof, M., Whelan, R. L., Sullivan, K. M., Ruel, C., Frankel, P. H., Cole, S., Tinsley, R., Eng, M., Fakih, M., Chao, J., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13941-2 · Cited by 42
Current and future biomarkers in the treatment of colorectal cancer
Cuyle, P.-J. A., & Prenen, H. (2016) · Acta Clinica Belgica · doi:10.1080/17843286.2016.1262996 · Cited by 43
Self-citationAn Update on Colorectal Cancer
Xue, L., Williamson, A. J., Gaines, S., Andolfi, C., Paul-Olson, T., Neerukonda, A. R., Steinhagen, E. F., Smith, R. K., Cannon, L. M., Polite, B. N., et al. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.02.003 · Cited by 42
Chu, J. N., Choi, J., Ostvar, S., Torchia, J. A., Reynolds, K. L., Tramontano, A. C., Gainor, J. F., Chung, D. C., Clark, J. W., & Hur, C. (2018) · Cancer · doi:10.1002/cncr.31795 · Cited by 39
Sadeghlar, F., Vogt, A., Mohr, R. U., Mahn, R., van Beekum, K., Kornek, M., Weismüller, T. J., Branchi, V., Matthaei, H., Toma, M. I., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02746-x · Cited by 38
Napolitano, S., Ciardiello, D., Falco, V. D., Martini, G., Martinelli, E., Corte, C. M. D., Esposito, L., Famiglietti, V., Liello, A. D., Avallone, A., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34632 · Cited by 41
Cleary, J. M., Rosen, L. S., Yoshida, K., Rasco, D. W., Shapiro, G. I., & Sun, W. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0409-9 · Cited by 37
Self-citationAngelucci, A., Monache, S. D., Cortellini, A., Padova, M. D., & Ficorella, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010299 · Cited by 45
Morano, F., Corallo, S., Niger, M., Barault, L., Milione, M., Berenato, R., Moretto, R., Randon, G., Antista, M., Belfiore, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy197 · Cited by 39
Self-citationDoes Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes?
Berges-Gimeno, M., Carpio-Escalona, L., Longo-Muñoz, F., Bernal-Rubio, L., López-González, P., Gehlhaar, P., Pachón, V., Ferreiro, R., Madrigal‐Burgaleta, R., & Álvarez-Cuesta, E. (2019) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0425 · Cited by 37
Kasi, P. M., & Grothey, A. F. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000195 · Cited by 41
The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer
Su, C., Olsen, K. A., Bond, C., & Whitehall, V. (2023) · Cancers · doi:10.3390/cancers15030805 · Cited by 40
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies
Peters, G. J. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015603313 · Cited by 39
AACR Cancer Progress Report 2016
Davidson, N. E., Armstrong, S. A., Coussens, L. M., Cruz-Correa, M. R., DeBerardinis, R. J., Doroshow, J. H., Foti, M., Hwu, P., Kensler, T. W., Morrow, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1993 · Cited by 44
Lombardi, P., Marandino, L., Luca, E. D., Zichi, C., Reale, M. L., Pignataro, D., Stefano, R. F. D., Ghisoni, E., Mariniello, A., Trevisi, E., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102877 · Cited by 38
Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial
Bragagnoli, A. S. C., Araújo, R. L. C., Ferraz, M. W. S., dos Santos, L. V., Abdalla, K. C., Comar, F., Santos, F. A., de Oliveira, M. A., Carvalheira, J. B. C., Cárcano, F. M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01208-6 · Cited by 40
Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
Ciardiello, D., Martini, G., Famiglietti, V., Napolitano, S., Falco, V. D., Troiani, T., Latiano, T. P., Ros, J., Élez, E., Vitiello, P. P., et al. (2021) · Cancers · doi:10.3390/cancers13081941 · Cited by 38
Advances in immunotherapy for MMR proficient colorectal cancer
Lote, H., Starling, N., Pihlak, R., & Gerlinger, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102480 · Cited by 38
Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs
Becker, D. J., Lin, D., Lee, S. Y., Levy, B. P., Makarov, D. V., Gold, H. T., & Sherman, S. E. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.020339 · Cited by 36
Liang, L., Wang, L., Zhu, P., Xia, Y., Qiao, Y., Wu, J., Zhuang, W., Fei, J., Wen, Y., & Jiang, X. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.011 · Cited by 36
Goel, S., Ocean, A. J., Parakrama, R. Y., Ghalib, M. H., Chaudhary, I., Shah, U., Viswanathan, S., Kharkwal, H., Coffey, M. C., & Maitra, R. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1117 · Cited by 36
Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development
Singh, D., Dheer, D., Samykutty, A. K., & Shankar, R. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.006 · Cited by 36
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
Aranda, E., Aparicio, J., Alonso, V., García‐Albéniz, X., Alfonso, P. G., Salazar, R., Valladares, M., Vera, R., Viéitez, J. M., & García‐Carbonero, R. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1434-4 · Cited by 40
Bierbaum, V., Bobeth, C., Roessler, M., Gerken, M., Tol, K. K.-V., Reißfelder, C., Fürst, A., Günster, C., Dröge, P., Ruhnke, T., et al. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03262-9 · Cited by 34
Doi, T., Yoshino, T., Fuse, N., Boku, N., Yamazaki, K., Koizumi, W., Shimada, K., Takinishi, Y., & Ohtsu, A. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0271-1 · Cited by 36
Self-citationAarnoutse, R., de Vos‐Geelen, J., Penders, J., Boerma, E.-J. G., Warmerdam, F. A. R. M., Goorts, B., Damink, S. W. M. O., Soons, Z. I. T. A., Rensen, S. S., & Smidt, M. L. (2017) · International Journal of Colorectal Disease · doi:10.1007/s00384-017-2819-3 · Cited by 35
Matsuoka, K., Nakagawa, F., Kobunai, T., & Takechi, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24412 · Cited by 36
Targeting KRAS in Colorectal Cancer
Wang, C., & Fakih, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01022-0 · Cited by 37
Saunders, M. P., Graham, J., Cunningham, D., Plummer, R., Church, D. N., Kerr, R. S., Cook, S., Zheng, S. S., Thangue, N. B. L., & Kerr, D. J. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100594 · Cited by 33
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
Zappi, A., Persano, I., Galvani, L., Parlagreco, E., Andrini, E., Campana, D., Brizzi, M. P., Lamberti, G., & Salvia, A. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020717 · Cited by 37
Longo-Muñoz, F., Argilés, G., Tabernero, J. M., Cervantes, A. M. R., Grávalos, C., Pericay, C., Calle, S. G., Mizuguchi, H., Carrato, A., Limón, M. L., et al. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1528-7 · Cited by 34
Self-citationPractical considerations in the use of regorafenib in metastatic colorectal cancer
Loupakis, F., Antonuzzo, L., Bachet, J., Kuan, F., Macarulla, T. M., Pietrantonio, F., Xu, R., Taniguchi, H., Winder, T. L., Yuki, S., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920956862 · Cited by 36
Amatu, A., Mauri, G., Tosi, F., Bencardino, K. B., Bonazzina, E. F., Gori, V., Ruggieri, L., Arena, S., Bardelli, A., Marsoni, S., et al. (2022) · Cancers · doi:10.3390/cancers14051197 · Cited by 37
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation
Cecchin, E., Mattia, E. D., Ecca, F., & Toffoli, G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.07.001 · Cited by 33
Walter, T., Hawkins, N., Pollock, R. F., Colaone, F., Shergill, S., & Ross, P. J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03315-6 · Cited by 39
Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial
Cutsem, E. V., Falcone, A., García‐Carbonero, R., Komatsu, Y., Pastorino, A., Peeters, M., Shimada, Y., Yamazaki, K., Yoshino, T., Zaniboni, A., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000261 · Cited by 42
Self-citationManaging 5FU Cardiotoxicity in Colorectal Cancer Treatment
Anaka, M., & Abdel-Rahman, O. (2022) · Cancer Management and Research · doi:10.2147/cmar.s273544 · Cited by 32
Cofano, F., Monticelli, M., Ajello, M., Zenga, F., Marengo, N., Perna, G. D., Altieri, R., Cassoni, P., Bertero, L., Melcarne, A., et al. (2019) · Cancer Control · doi:10.1177/1073274819870549 · Cited by 33
Nucleosides are overlooked fuels in central carbon metabolism
Strefeler, A., Blanco-Fernández, J., & Jourdain, A. A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.01.013 · Cited by 38
Kopetz, S., Boni, V., Kato, K., Raghav, K. P. S., Vieito, M., Pallis, A. G., Habermehl, C., Siddiqui, A., Courlet, P., Sloot, W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03843-z · Cited by 41
Nukatsuka, M., Nakagawa, F., & Takechi, T. (2015) · PubMed · Cited by 31
Oki, E., Makiyama, A., Miyamoto, Y., Kotaka, M., Kawanaka, H., Miwa, K., Kabashima, A., Noguchi, T., Yuge, K., Kashiwada, T., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3618 · Cited by 31
Vafopoulou, P., & Kourti, M. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.08 · Cited by 32
Xu, X., Ai, L., Hu, K., Liang, L., Lv, M., Wang, Y., Cui, Y., Li, W., Li, Q., Yu, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51536-x · Cited by 29
Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Murgioni, S., Rossini, D., Marmorino, F., Mennitto, A., Ning, Y., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx035 · Cited by 30
Self-citationCascinu, S., Rosati, G., Nasti, G., Lonardi, S., Zaniboni, A., Marchetti, P., Leone, F., Bilancia, D., Iaffaioli, R. V., Zagonel, V., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.029 · Cited by 31
Self-citationKeller, F., & Hann, A. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10960917 · Cited by 30
Combinatorial Immunotherapies for Metastatic Colorectal Cancer
Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 34
Yang, K., Han, L., Wu, S., Qu, X., Li, Q., Zhao, C., Zhou, J., Jin, X. S., Wang, Y., Dong, Y., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03083-3 · Cited by 33
Yoshino, T., Uetake, H., Fujita, N., Furuta, T., Katori, J., Hara, N., & Muro, K. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.04.004 · Cited by 30
Self-citationMatsuda, A., Yamada, T., Matsumoto, S., Sakurazawa, N., Kawano, Y., Shinozuka, E., Sekiguchi, K., Suzuki, H., & Yoshida, H. (2019) · Anticancer Research · doi:10.21873/anticanres.13602 · Cited by 30
Pietrantonio, F., Randon, G., Romagnoli, D., Donato, S. D., Benelli, M., & de Braud, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101935 · Cited by 29
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 32
An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma
Ikoma, N., Raghav, K. P. S., & Chang, G. J. (2017) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.05.007 · Cited by 39
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal
Upshaw, J. N., O’Neill, A., Carver, J. R., Dimond, E. P., Denlinger, C. S., Kircher, S. M., Wagner, L. I., Ky, B., & Brell, J. M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.08.001 · Cited by 30
Bullement, A., Underhill, S., Fougeray, R., & Hatswell, A. J. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.09.001 · Cited by 30
Selecting treatment options in refractory metastatic colorectal cancer
Byrne, M. M., & Saif, M. W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194605 · Cited by 28
Montés, A. F., Grávalos, C., Pericay, C., Safont, M. J., Benavides, M., Élez, E., Alfonso, P. G., García-Paredes, B., Carrato, A., & Aranda, E. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.04.003 · Cited by 29
Liu, Y., Lyu, J., Burdett, K. B., Sibley, A. B., Hatch, A. J., Starr, M. D., Brady, J. C., Hammond, K., Marmorino, F., Rossini, D., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0249 · Cited by 29
Self-citationSuetsugu, T., Mori, R., Futamura, M., Fukada, M., Tanaka, H., Yasufuku, I., Sato, Y., Iwata, Y., Imai, T., Imai, H., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.7978 · Cited by 33
Dueland, S., Smedman, T. M., Røsok, B. I., Grut, H., Syversveen, T., Jørgensen, L. H., & Line, P. (2021) · Transplant International · doi:10.1111/tri.13995 · Cited by 29
Emerging Therapeutic Agents for Colorectal Cancer
Nalli, M., Puxeddu, M., Regina, G. L., Gianni, S., & Silvestri, R. (2021) · Molecules · doi:10.3390/molecules26247463 · Cited by 29
Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer
Bera, H., & Chigurupati, S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.032 · Cited by 29
Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion
Zervoudakis, A., Boucher, T. M., & Kemeny, N. E. (2017) · Visceral Medicine · doi:10.1159/000454693 · Cited by 28
Patel, A. K., Abhyankar, R., Brais, L. K., Duh, M. S., Barghout, V. E., Huynh, L. Y., Yenikomshian, M. A., Ng, K., & Fuchs, C. S. (2021) · The Oncologist · doi:10.1002/onco.13942 · Cited by 27
Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Pietrantonio, F., Avallone, A., Maiello, E., Cremolini, C., Troiani, T., Martinelli, E., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.01.005 · Cited by 32
Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
Lopes, B. A., Poubel, C. P., Teixeira, C. E., Caye‐Eude, A., Cavé, H., Meyer, C., Marschalek, R., Boroni, M., & Emerenciano, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.749472 · Cited by 29
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.